Swedbank AB Buys 43,205 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Swedbank AB increased its stake in Gilead by 1.8% in Q4, buying 43,205 shares and now holds 2,505,240 shares valued at about $307.5 million (≈0.20% of the company).
• Company insiders have been sellers recently—including CFO Andrew Dickinson and Johanna Mercier—with insiders offloading a total of 178,640 shares (~$26.6 million) in the last 90 days, leaving insiders with roughly 0.30% ownership.
• Analysts are broadly constructive: Gilead beat Q results and set FY2026 EPS guidance of 8.45–8.85, and the stock carries a consensus rating of "Moderate Buy" with a consensus price target of $157.35.

Swedbank AB lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,505,240 shares of the biopharmaceutical company's stock after purchasing an additional 43,205 shares during the period. Swedbank AB owned 0.20% of Gilead Sciences worth $307,493,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Corundum Trust Company INC bought a new stake in Gilead Sciences during the 3rd quarter valued at $26,000. Ares Financial Consulting LLC bought a new position in shares of Gilead Sciences during the 4th quarter worth $28,000. Financial Consulate Inc. grew its position in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 109 shares in the last quarter. North Star Investment Management Corp. increased its stake in shares of Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 86 shares during the period. Finally, MTM Investment Management LLC increased its stake in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 176 shares during the period. Institutional investors own 83.67% of the company's stock.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the transaction, the chief financial officer directly owned 176,191 shares of the company's stock, valued at approximately $24,835,883.36. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the transaction, the insider directly owned 120,288 shares in the company, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 178,640 shares of company stock worth $26,584,250 in the last 90 days. 0.30% of the stock is owned by corporate insiders.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: AHF says Gilead’s EPS could rise ~52% because state AIDS drug program shortfalls have increased reliance on commercial/retail supply, implying near-term revenue upside for Gilead’s HIV portfolio. Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF
• Positive Sentiment: Brokerage commentary and price-target coverage are constructive — a recent note cites a $157.35 target, supporting investor expectations of upside versus current levels. Brokerages Set Gilead Sciences, Inc. NASDAQ: GILD Price Target at $157.35
• Neutral Sentiment: Use of Yeztugo (twice-yearly HIV-prevention shot) is rising since launch, which supports Gilead’s growth story in prevention, but adoption is still early and incremental to overall revenues. Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain
• Neutral Sentiment: Analyst/estimate deep dives (Zacks/market write-ups) are circulating ahead of quarterly reporting; these pieces highlight key metrics investors will watch (sales mix of HIV products, hepatitis/oncology performance, and guidance). That keeps focus on fundamentals rather than a single headline. Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Brand/marketing recognition (PLAN C Impact 50) is positive for awareness but unlikely to move near-term fundamentals materially. Eight PLAN C Client Brands Named to the 3AF 2026 Impact 50
• Negative Sentiment: Insurance coverage gaps for Yeztugo remain a real constraint — patients who want the injection can face reimbursement hurdles, which could cap upside in medium-term prevention revenue if not resolved. Use of Gilead's HIV prevention shot rises, but US insurance gaps remain

Gilead Sciences Price Performance

GILD opened at $133.48 on Wednesday. The firm has a market capitalization of $165.68 billion, a PE ratio of 19.72, a price-to-earnings-growth ratio of 1.75 and a beta of 0.31. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The business's 50-day moving average is $140.14 and its two-hundred day moving average is $132.66. Gilead Sciences, Inc. has a 1 year low of $95.29 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period in the prior year, the firm posted $1.90 earnings per share. The company's quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

GILD has been the subject of a number of research reports. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a "neutral" rating in a research note on Friday, April 17th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a "buy" rating in a research report on Wednesday, February 11th. UBS Group upped their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Oppenheimer increased their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an "outperform" rating in a research note on Wednesday, February 11th. Finally, Wolfe Research lifted their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an "outperform" rating in a report on Thursday, February 12th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $157.35.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.